Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant von Willebrand factor: preclinical development.

B Plaimauer1, U Schlokat, P L Turecek

  • 1Biomedical Research Center, Baxter AG, Hyland-Immuno Division, Orth/Donau, Austria.

Seminars in Thrombosis and Hemostasis
|September 8, 2001
PubMed
Summary

Recombinant von Willebrand factor (r-vWF) offers superior structural integrity and a longer half-life compared to plasma-derived treatments for von Willebrand disease (vWD). This novel therapeutic agent demonstrates significant potential for improved patient outcomes in managing bleeding disorders.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short communications: an ear-attached accelerometer detects effects of regrouping on lying, rumination, and activity times in calves.

Veterinary research communications·2023
Same author

Use of a real-time location system to detect cows in distinct functional areas within a barn.

JDS communications·2022
Same author

Erratum to "Use of a real-time location system to detect cows in distinct functional areas within a barn" (JDS Commun. 2:217-222).

JDS communications·2022
Same author

Monitoring selected behaviors of calves by use of an ear-attached accelerometer for detecting early indicators of diarrhea.

Journal of dairy science·2021
Same author

Comparison of behavioral patterns of dairy cows with natural estrus and induced ovulation detected by an ear-tag based accelerometer.

Theriogenology·2020
Same author

Evaluation of an ear-attached accelerometer for detecting estrus events in indoor housed dairy cows.

Theriogenology·2019

Area of Science:

  • Biochemistry
  • Hematology
  • Biotechnology

Background:

  • Von Willebrand disease (vWD) arises from defects in von Willebrand factor (vWF), a glycoprotein crucial for platelet adhesion and Factor VIII (FVIII) stabilization.
  • Current therapies using plasma-derived vWF concentrates often lack essential high-molecular-weight multimers due to manufacturing degradation, limiting efficacy.
  • Severe vWD necessitates effective substitution therapy to manage bleeding episodes.

Purpose of the Study:

  • To evaluate the therapeutic potential of recombinant von Willebrand factor (r-vWF) for treating von Willebrand disease.
  • To assess the structural integrity, functional activity, and in vivo efficacy of r-vWF compared to plasma-derived vWF.
  • To investigate the pharmacokinetic profile and therapeutic benefits of r-vWF in a preclinical model.

Related Experiment Videos

Main Methods:

  • Constitutive expression of r-vWF in Chinese hamster ovary (CHO) cells under perfusion fermentation in protein-free medium.
  • Functional assays assessing ristocetin cofactor activity, collagen binding, FVIII binding, and platelet-collagen adhesion under shear stress.
  • In vivo studies involving infusion of r-vWF into vWF-deficient animals to evaluate hemostatic parameters and FVIII stabilization.

Main Results:

  • r-vWF exhibited high-molecular-weight multimers with exceptional structural integrity.
  • Functional analyses confirmed r-vWF's ability to mediate platelet aggregation, collagen interaction, FVIII binding, and shear-dependent platelet adhesion.
  • Infusion of r-vWF in deficient animals corrected vWF levels, reduced blood loss, stabilized FVIII, and shortened bleeding times.
  • r-vWF demonstrated a prolonged half-life compared to plasma-derived vWF preparations.

Conclusions:

  • Recombinant von Willebrand factor (r-vWF) possesses superior structural and functional properties compared to plasma-derived vWF.
  • r-vWF effectively restores hemostasis and FVIII levels in vivo, indicating its therapeutic promise for von Willebrand disease.
  • The enhanced stability and prolonged half-life of r-vWF position it as a potentially valuable therapeutic agent for vWD patients.